Russian Federation: Import Substitution In The Pharmaceutical And Medical Industries In Russia: Legislative Developments And Initiatives

Last Updated: 30 October 2015
Article by Yana Dianova

Import substitution (a significant increase of the share of medicines and medical devices of Russian origin) in the pharmaceutical and medical industries is envisaged by:

  • the Strategy of Pharmaceutical Industry Development in the Russian Federation for the period up to 2020 approved by the Order of the Ministry of Industry and Trade of the Russian Federation (Minpromtorg) No. 965 dated 23 October 2009, under which localization of manufacturing and development of medicines in Russia is the first of three main stages;
  • the Federal Target Program 'Development of the Pharmaceutical and Medical Industry of the Russian Federation for the period up to 2020 and further' ('Pharma 2020') approved by the Resolution of the Government of the Russian Federation No. 91 dated 17 February 2011, and by the State Program of the Russian Federation 'Development of Pharmaceutical and Medical Industry' for 2013 - 2020 approved by the Resolution of the Government of the Russian Federation, No. 305 dated 15 April 2014, providing that by 2018 the share of domestic medicines under the nomenclature of the list of strategically important medicines and the list of vital and essential medicines shall be 90%, the share of domestic medical devices within the priority areas of healthcare - 22%.

The main directions of legal regulation of import substitution in Russia include:

  • creation of incentives for localization of production facilities by foreign manufacturers in the Russian Federation, including granting of subsidies for organisation of clinical trials and manufacturing of medicines and medical devices; 
  • restriction of the procurement of foreign goods for state and municipal needs.

The recent changes in laws and legislative initiatives in these areas are considered below in more detail.

Subsidies to the Russian manufacturers of medicines and medical devices and(or) pharmaceutical substances

On 1 October 2015, the Government of the Russian Federation adopted a number of resolutions to approve the procedures and conditions for granting subsidies from the federal budget to Russian organisations for partial compensation of costs:

1. related to the clinical trials of medicines: for the purchase of raw materials and consumables for producing samples of the developed medicine, for the purchase of comparator medicine, for the third-party services on laboratory, clinical and diagnostic trials and searches, processing of resulting findings, transport of clinical samples, as well as for premiums on insurance of life and health of patients participating in clinical trials of the medicine (Resolution No. 1045);

2. incurred in the implementation of projects for the production of medicines and(or) pharmaceutical substances under the list of vital and essential medicines (Resolution No. 1047). Subsidies are granted in respect of payments (except for initial payment) under equipment leases, for the third -party services on commissioning of equipment for the production of pharmaceutical substances, for the purchase of consumables, reagents for the production technology development, including the run of pre-production batches (validation series) of pharmaceutical substances, as well as for payment for other third-party services associated with the project;

3. incurred in the course of conducting clinical trials of medical devices included in the list of medical devices implanted into the human body when providing medical assistance under the program of state guarantees of free medical aid to citizens (Resolution No. 1046). The subsidies may be granted to Russian organisations possessing valid permits to conduct clinical trials of medical devices included in the list of medical devices implanted into the human body when providing medical assistance under the program of state guarantees of free medical care to citizens approved by the Government of the Russian Federation;

4. related to the organisation of high-tech manufacturing of medical devices in such areas as: medical devices implanted in the human body; disposable medical devices; consumables for medical devices; technical means of rehabilitation related to medical devices for handicapped persons and persons with disabilities; installations for high efficiency ion beam radiation therapy; medical devices for personal remote monitoring of patients; medical devices for ophthalmology (Resolution No. 1048). The subsidies are granted to Russian organisations with total revenue from the sale of medical devices of own production during 2012 - 2015 years in the amount not less than 100 million roubles and possessing at least one valid registration certificate for the medical devices manufactured thereby.

The subsidies are provided upon an application based on the agreement entered into between Minpromtorg and a Russian organisation.

The Resolutions establish the following general rules for granting subsidies:

a. an organisation applying for a subsidy must be registered in the Russian Federation and possess a license for manufacturing of medicines for medical use (according to the Resolutions No. 1045 and No. 1047) or medical devices (according to the Resolution No. 1048), respectively;

b. the business plan must stipulate the release into circulation of a pharmaceutical substance or medical device manufactured under the project not later than within 3 years after entering into the agreement for granting of the subsidy;

c. subsidies are granted in respect of the costs of Russian organisations actually incurred on or after 1 January 2015, confirmed by documents, related to the project and provided for by the business plan;

d. subsidies will cover no more than 50% of the total costs and no more than 200 million roubles (5 million - in case of clinical trials of implantable medical devices) per a legal entity.

'Third Weird': Restrictions in Public and Municipal Procurement

Article 14 of the Federal Law No. 44-FZ 'On the Contract System in the Area of Procurement of Goods, Works and Services for Public and Municipal Needs' (Law No. 44-FZ) provides for the right of the Government of the Russian Federation to impose a ban on the admission of goods originating from foreign countries and to restrict the admission of such goods for the purposes of the relevant procurement.

Based on the above provisions of the Law No. 44-FZ, the Government of the Russian Federation adopted the Resolution No. 102 dated 5 February 2015 which provides for the obligation of a customer in the course of procurement of medical devices included in the list approved by this resolution for public and municipal needs to reject all tender bids for the supply of medical devices originating from foreign countries, except for Armenia, Belarus and Kazakhstan, provided that there are at least two bids that simultaneously meet the following requirements:

  • contain offers of the supply of the medical device(s) included in the list and originating from Russia, Armenia, Belarus or Kazakhstan;
  • do not contain offers for the supply of the same type of medical device of the same manufacturer.

By the end of this year, the Government of the Russian Federation is to adopt another Resolution (a so -called 'Third Weird') providing that from 1 January 2016 in the course of procurement of a medicine for public and municipal needs by way of a tender or auction, the restrictions on admission of the bids for the supply of the following medicines will apply:

  • originating from foreign countries (except for Armenia, Belarus and Kazakhstan);
  • in respect of which in the territory of Russia and(or) Armenia, Belarus, Kazakhstan only the stages 'primary packaging' and(or) 'secondary packaging' of technological process are effected,

in the event there are two or more bids filed by different manufacturers for the supply of medicines originating from Russia and(or) Armenia, Belarus, Kazakhstan, and in the territory of the relevant country the technological process stage 'production of the finished dosage form' is performed.

The procedure for confirmation of the technological process stages of manufacturing of medicines, including the stages of production of active pharmaceutical ingredients, should be approved by Minpromtorg by 1 January 2016.

The respective draft regulatory act provides that medicines, serums and vaccines will be deemed the goods of the Russian origin based on the criteria of 'the technological process stages performed in the Russian Federation' as well as the criteria of their state registration in Russia.

The stages will be divided into 'production of the finished dosage form' and 'packaging'. From 1 January 2016 the goods manufactured in Russia are to include only medicines with respect to which both these stages are performed in the Russian Federation.

In addition, the Ministry of Economic Development of the Russian Federation and Minpromtorg shall by 1 January 2016 adopt the regulatory act establishing the differentiated scale of preferences depending on the technological process stage of manufacturing of a medicine for the purposes of determining a contract price in the course of state and municipal procurement.

According to the Head of the Department of Development of Pharmaceutical and Medical Industry of Minpromtorg, the medicines not covered by the 'Third Weird' Resolution will be subject to the 15% preference related to the contract price under the Order of the Russian Ministry of Economic Development 'On Conditions for the Admission of Goods Originating from Foreign Countries, for the Purposes of the Procurement of Goods, Works and Services for Public and Municipal Needs' No. 155 dated 25 March 2014.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions